Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-Current Deferred Tax Liability (2023 - 2024)

Historic Non-Current Deferred Tax Liability for Gyre Therapeutics (GYRE) over the last 2 years, with Q4 2024 value amounting to $8.3 million.

  • Gyre Therapeutics' Non-Current Deferred Tax Liability rose 23200.0% to $8.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.3 million, marking a year-over-year increase of 23200.0%. This contributed to the annual value of $8.3 million for FY2024, which is 23200.0% up from last year.
  • As of Q4 2024, Gyre Therapeutics' Non-Current Deferred Tax Liability stood at $8.3 million, which was up 23200.0% from $2.5 million recorded in Q4 2023.
  • Over the past 5 years, Gyre Therapeutics' Non-Current Deferred Tax Liability peaked at $8.3 million during Q4 2024, and registered a low of $2.5 million during Q4 2023.